Patterns of practice survey for nonsmall cell lung carcinoma in the U.S.

Cancer

Volumn 88, Issue 6, 2000, Pages 1336-1346

  Choy, Hak ^a   Shyr, Yu ^a   Cmelak, Anthony J ^a   Mohr, Peter J ^a   Johnson, David H ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Combined modality; Data collection; Nonsmall cell lung carcinoma (NSCLC); Practice patterns; Questionnaires

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CANCER THERAPY; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; MEDICAL PRACTICE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; CISPLATIN; CLINICAL PROTOCOLS; DECISION MAKING; DIAGNOSTIC IMAGING; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; NEOPLASM STAGING; PACLITAXEL; PHYSICIAN'S PRACTICE PATTERNS; RADIATION ONCOLOGY; RADIOTHERAPY, ADJUVANT; UNITED STATES;

EID: 0034653830     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000315)88:6<1336::AID-CNCR9>3.0.CO;2-M     Document Type: Article

References (25)

1. Kaiser LR, Friedberg JS. The role of surgery in the multimodality management of non-small cell lung cancer. Semin Thorac Cardiovasc Surg 1997;9:60-79.
2. Belani CP. Multimodality management of regionally advanced non-small-cell lung cancer. Semin Oncol 1993;20: 302-14.
3. Raby B, Pater J, Mackillop WJ. Does knowledge guide practice? Another look at the management of non-small-cell lung cancer. J Clin Oncol 1995;13:1904-11.
4. Crook A, Duffy A, Girling DJ, Souhami RL, Parmar MKB. Survey on the treatment of non-small cell lung cancer (NSCLC) in England and Wales. Eur Respir J 1997;10:1552-8.
5. Blumenstein BA. Verifying keyed medical research data. Stat Med 1993;12:1535-42.
6. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
7. Diggle P, Liang KY, Zeger SL. Analysis of longitudinal data. Oxford: Clarendon Press, 1994.
8. American Thoracic Society/European Respiratory Society. Pretreatment evaluation of non-small-cell lung cancer. Am J Respir Crit Care Med 1997;156:320-32.
9. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940-5.
10. Dillman RO, Herndon J, Seagren SL, Eaton WL, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial. J Natl Cancer Inst 1996;88:1210-5.
11. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer [abstract]. J Clin Oncol 1999;17:2692.
12. Byhardt RW, Scott C, Sause WT, Emami B, Russell AH, Fu KK, et al. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1998;42:469-78.
13. RTOG-9410 Protocol. Phase III randomized study of standard thoracic irradiation following VBL/CDDP vs standard thoracic irradiation and concurrent VBL/CDDP vs hyperfractionated thoracic irradiation and concurrent VP-16/ CDDP for locally advanced, unresectable, non-small cell lung cancer. Current Clinical Trials Oncology. Available at URL: http://cancernet.nci.gov/prot/protsrch.shtml [accessed July 1998].
14. Belani CP, Aisner J, Bahri S, Jett J, Day R, Capazolli MJ, et al. Chemoradiotherapy in non-small cell lung cancer: paclitaxel/carboplatin/radiotherapy in regionally advanced disease. Semin Oncol 1996;23(Suppl 16):113-6.
15. Hainsworth JD, Urba WJ, Hon JK, Thompson KA, Stagg MP, Hopkins LG, et al. One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicentre, phase II trial. Eur J Cancer 1998;34:654-8.
16. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, et al. Paclitaxel and Carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860-70.
17. Johnson DH, Paul DM, Hande KR, Shyr Y, Blanke C, Murphy B, et al. Paclitaxel plus carboplatin in advanced non-small cell lung cancer. A phase II trial. J Clin Oncol 1996;14:2054-60.
18. Choy H, DeVore RD, Hande KR, Porter LL, Rosenblatt PA, Yunus F, et al. Phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy in locally advanced inoperable non-small cell lung cancer: a Vanderbilt Cancer Center Affiliate Network (VCCAN) trial [abstract 1794]. Proc Am Soc Clin Oncol 1998;17:467a.
19. Greco FA, Hainsworth JD. Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter phase II trial. Semin Oncol 1997;24 (Suppl 12):S12-7.
20. Evans WK, Earle CC, Stewart DJ, Dahrouge S, Tomiak E, Goss GL, et al. Phase II study of a one hour paclitaxel infusion in combination with carboplatin for advanced non-small cell lung cancer. Lung Cancer 1997;18:83-94.
21. Kosmidis PA, Mylonakis N, Fountzilas G, Samantas E, Athanasiadis A, Andreopoulou E, et al. Paclitaxel and carboplatin in inoperable non-small cell lung cancer: a phase II study. Ann Oncol 1997;8:697-9.
22. Roychowdhury DF, Desai P, Zhu Y-W. Paclitaxel (3-hour infusion) followed by carboplatin (24 hours after paclitaxel): a phase II study in advanced non-small cell lung cancer. Semin Oncol 1997;24 (Suppl 12):S12-37-40.
23. Johnson DH, Zhu J, Schiller J, Belani CP, Langer C, Krook J, et al. E1594-A randomized phase III trial in metastatic non-small cell lung cancer (NSCLC)-outcome of PS 2 patients (pts): An Eastern Cooperative Group trial (ECOG) [abstract 1779]. Proc Am Soc Clin Oncol 1999;18:461a.
24. Kelly K, Crowley J, Bunn PA, Livingston DR, Gandara DR. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): a Southwest Oncology Group (SWOG) trial [abstract 1777]. Proc Am Soc Clin Oncol 1999;18:461a.
25. Perez EA. Perceptions of prognosis, treatment and treatment impact on prognosis in non-small cell lung cancer. Chest 1998;114:593-604.